达格列净起始后eGFR早期下降与HFrEF患者结局:DAPA-HF事后分析
该DAPA-HF事后分析评估HFrEF患者起始达格列净后eGFR早期下降的发生率及其与结局的关联。达格列净组eGFR平均下降幅度大于安慰剂组,但发生>10%下降者的主要结局风险在达格列净组反而更低,且未增加长期eGFR下降或不良事件。
要点
- 达格列净起始后2周eGFR平均下降4.2,安慰剂组下降1.1,组间差3.1。
- 达格列净组>10%早期eGFR下降者主要结局风险低于安慰剂组同类下降者。
- 早期eGFR下降不增加长期eGFR下降或不良事件风险。
核心结论
- 达格列净起始后eGFR平均下降幅度小,且与安慰剂相比,相似下降幅度下达格列净组临床结局更优。
- 达格列净组发生大幅eGFR下降不常见。
研究设计与样本
- DAPA-HF试验事后分析,纳入HFrEF且eGFR≥30 mL·min-1·1.73 m-2患者,随机接受安慰剂或达格列净10 mg每日一次。
- 主要结局为心衰恶化或心血管死亡复合终点。
- 分析基线与2周eGFR下降幅度、与>10%下降相关的特征及结局。
主要发现
- 第0至14天eGFR平均变化:安慰剂组-1.1 mL·min-1·1.73 m-2(95%CI -1.5至-0.7),达格列净组-4.2 mL·min-1·1.73 m-2(95%CI -4.6至-3.9),组间差3.1 mL·min-1·1.73 m-2(95%CI 2.6-3.7)。
- 达格列净组eGFR下降>10%、>20%、>30%的比例分别为38.2%、12.6%、3.4%;安慰剂组分别为21.0%、6.4%、1.3%。
- 达格列净相比安慰剂发生>10%早期eGFR下降的OR为2.36(95%CI 2.07-2.69;P<0.001)。
- 达格列净组>10%下降相关基线特征:年龄较大、eGFR较低、射血分数较高、2型糖尿病。
- 安慰剂组>10%下降者主要结局HR为1.45(95%CI 1.19-1.78);达格列净组相应HR为0.73(95%CI 0.59-0.91;Pinteraction<0.001)。
临床怎么用
- 达格列净起始后eGFR早期下降幅度通常较小,不应因此常规停药。
- 发生>10%早期eGFR下降不提示长期肾功能恶化或不良事件增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a post hoc analysis, the frequency of occurrence of an early decline (dip) in estimated glomerular filtration rate (eGFR) after initiation of dapagliflozin and its association with outcomes were evaluated in patients with heart failure and reduced ejection fraction randomized in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial. METHODS: Patients with heart failure with reduced ejection fraction with or without type 2 diabetes and an eGFR ≥30 mL·min-1·1.73 m-2 were randomized to placebo or dapagliflozin 10 mg daily. The primary outcome was the composite of worsening heart failure or cardiovascular death. The extent of the dip in eGFR between baseline and 2 weeks, patient characteristics associated with a >10% decline, and cardiovascular outcomes and eGFR slopes in participants experiencing this decline were investigated. Time-to-event outcomes were assessed in Cox regression from 14 days; eGFR slopes were assessed with repeated-measures mixed-effect models. RESULTS: The mean change in eGFR between day 0 and 14 was -1.1 mL·min-1·1.73 m-2 (95% CI, -1.5 to -0.7) with placebo and -4.2 mL·min-1·1.73 m-2 (95% CI, -4.6 to -3.9) with dapagliflozin, giving a between-treatment difference of 3.1 mL·min-1·1.73 m-2 (95% CI, 2.6-3.7). The proportions of patients randomized to dapagliflozin experiencing a >10%, >20%, and >30% decline in eGFR were 38.2%, 12.6%, and 3.4%, respectively; for placebo, they were 21.0%, 6.4%, and 1.3%, respectively. The odds ratio for a >10% early decline in eGFR with dapagliflozin compared with placebo was 2.36 (95% CI, 2.07-2.69; P<0.001). Baseline characteristics associated with a >10% decline in eGFR on dapagliflozin were older age, lower eGFR, higher ejection fraction, and type 2 diabetes. The hazard ratio for the primary outcome in patients in the placebo group experiencing a >10% decline in eGFR compared with ≤10% decline in eGFR was 1.45 (95% CI, 1.19-1.78). The corresponding hazard ratio in the dapagliflozin group was 0.73 (95% CI, 0.59-0.91; Pinteraction<0.001). A >10% initial decline in eGFR was not associated with greater long-term decline in eGFR or more adverse events. CONCLUSIONS: The average dip in eGFR after dapagliflozin was started was small and associated with better clinical outcomes compared with a similar decline on placebo in patients with heart failure with reduced ejection fraction. Large declines in eGFR were uncommon with dapagliflozin. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03036124.
引用
- Adamson, Docherty, Heerspink, et al. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation. 2022. PMID: 35442064. doi:10.1161/CIRCULATIONAHA.121.058910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。